Other News To Note
Agios Pharmaceuticals Inc., of Cambridge, Mass., said a recent publication highlighted the discovery of the first potent inhibitors of mutant isocitrate dehydrogenase (IDH) that lower tumor 2-HG in vivo.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.